Navigation Links
Biondvax's Universal Flu Vaccine Receives Additional US Patent
Date:1/27/2016

NESS ZIONA, Israel, January 27, 2016 /PRNewswire/ --

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) developer of a Universal Flu Vaccine currently undergoing late-stage 2 clinical trials, announced today that its patent application in the United States titled "Multimeric Multi-Epitope Polypeptides in Improved Seasonal and Pandemic Influenza Vaccines" has completed examination and is allowed for issuance as a patent.

The invention covers the use of BiondVax's universal flu vaccine as a prime-boost to the current commercially available flu vaccine. Results from BiondVax's completed clinical trials have shown significantly increased effectiveness against multiple flu strains.  

Ron Babecoff, CEO of BiondVax commented, "Current flu vaccines are strain specific and are not particularly effective against circulating 'wild-type' strains due to mismatches. In fact, last year's seasonal flu vaccine was only 23% effective[1]. Conversely, our vaccine provides long-lasting and higher effectiveness against multiple flu strains."

Continued Dr. Babecoff, "Our newly approved US patent demonstrates the novel nature of our vaccine technology and strengthens our IP portfolio for many years to come."

About BiondVax Pharmaceuticals Ltd. 

BiondVax is a biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. For more information, please visit http://www.biondvax.com .

[1] http://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm

Forward Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome, BiondVax's ability to continue obtaining and maintaining intellectual property protection for our Universal Flu Vaccine, risks inherent in the development and commercialization of potential products, dependence upon collaborators, and adequacy of capital resources for product development and commercialization. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements. 

For further information, please contact:

Company Contact
Joshua Phillipson
Business Development  Manager
+972-8-930-2529 x5105
j.phillipson@biondvax.com

Investor Relations Contact
GK Investor Relations
Kenny Green, Partner
+1-646-201-9246
kenny@biondvax.com


'/>"/>
SOURCE BiondVax Pharmaceuticals Ltd.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Finesse Solutions Launches Next Generation G3Lab Universal SmartControllers to Enhance Productivity in Bench Scale Cell Culture and Fermentation
2. Inovios Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals
3. Drug Launch, Market Activity, Appointments, and Special Meeting of Shareholders - Research Reports on Teva, Universal Health, Tenet, Allergan and Valeant
4. Universal Health Services Inc (UHS: NYS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry
5. Westone Revolutionizes Universal-Fit Ear Protection For Firearms with New DefendEar Digital Shooter
6. Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle
7. BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults
8. NeuroPhages NPT088 Universally Targets Misfolded Proteins in Preclinical Studies Highlighted in Oral Session at the Alzheimers Association International Conference
9. Independent Results Show that BiondVaxs Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic
10. Global Medical Lifting Sling Market 2015: Transfer, Hammock, Toilet, Seating, Universal, Standing, Bariatric Analysis of the $706 Million Industry
11. Research Team Publishes New Methods for Synthetic Generation of Influenza Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2019)... MIRADA, Calif. (PRWEB) , ... August 16, 2019 ... ... their new psychological service, Eye Movement Desensitization and Reprocessing therapy (EMDR). This therapeutic ... EMDR is an evidence-based practice used for post-traumatic stress disorder (PTSD), depression, chronic ...
(Date:8/16/2019)... ... August 16, 2019 , ... Sacramento-based physician recruiting firm, MDstaffers , ... by Inc. magazine. MDstaffers three-year growth of more than 5,600 percent made it the ... human resources company had it competed in this category. This news comes nine-years after ...
(Date:8/16/2019)... ... August 16, 2019 , ... Today, Point-of-Care Partners announced Government ... has joined the company as a Government Affairs and Health IT Strategist. In ... standards organizations to advance use of health IT for comprehensive medication management. , ...
Breaking Medicine Technology:
(Date:8/21/2019)... ... 21, 2019 , ... Crowdfunders suffering from stress, back and ... Kickstarter (nearly 10-times its campaign goal) for GoRelax – an innovative lightweight ... , “We created GoRelax after realizing that acupressure mats are commonly used by ...
(Date:8/21/2019)... ... August 21, 2019 , ... Calling ... Hospice & Palliative Care’s Veterans and First Responders Recognition Ceremony on Wednesday, September ... residents representing all branches of the military and law enforcement are expected to ...
(Date:8/21/2019)... ... August 21, 2019 , ... Photoprotective Technologies (PPT) has just ... water-based ingredient is currently used in skincare products such as creams or makeup and ... addresses the growing need to protect the skin from blue light as well as ...
(Date:8/21/2019)... ... August 21, 2019 , ... Future residents got ... The Phase II expansion of Providence Point in Pittsburgh’s Scott Township neighborhood involved ... of the 70-unit apartment tower, Hamilton Tower. , The expansion began ...
(Date:8/19/2019)... ... 19, 2019 , ... American Society for Dermatologic Surgery (ASDS) ... 2018 – 7.5 percent more than 2017 and a 60 percent increase since ... Dermatologic Procedures revealed skin cancer treatments are persistently the most-performed procedure with ...
Breaking Medicine News(10 mins):